Shortened treatment for low-level cryptococcal infection in HIV
Part of Brain & nervous system, Infections clinical trials.
This study tests whether a shorter course of an antifungal drug (fluconazole) plus earlier HIV treatment is safe and works as well as the standard approach for people with HIV who have a low level of cryptococcal antigen in their blood. It aims to prevent a serious fungal infection from developing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are HIV positive.
- You are 18 years old or older.
- A blood test shows you have a low level of cryptococcal antigen (a sign of a fungal infection).
- You have not had a cryptococcal infection before.
- You do not have symptoms of meningitis (like severe headache, stiff neck, or light sensitivity).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a one-time antifungal treatment can help people with HIV who have a positive cryptococcal antigen blood test but no symptoms. It may lower the chance that this infection becomes a serious illness affecting the brain.
This trial is testing new treatments for cryptococcal meningitis, a serious brain infection, in people living with HIV. It aims to find the best way to treat this infection with fewer side effects.
This is an early-stage trial testing a new experimental drug (IAP-086-1) in people with HIV who have their virus well-controlled on current medications. Researchers want to understand how safe the drug is and how the body handles it.
This trial compares two antifungal medicines to treat talaromycosis, a serious fungal infection common in people with HIV. It tests whether a shorter course of treatment with two medicines is as good as the standard approach, which may help reduce side effects and hospital time.
This trial compares a shorter course of antifungal medicine to a longer one for people who have candidemia (a yeast infection in the blood). It looks at whether treating for a shorter time is just as safe and effective, which could mean fewer side effects and a quicker recovery.
This trial tests a one-time high dose of an antifungal medicine (liposomal amphotericin B) combined with a standard HIV treatment (B/F/TAF) for people with HIV who also have talaromycosis, a serious fungal infection. The goal is to see if this approach is safe and effective.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.